Bansidhar Tarai

Dr. Bansidhar Tarai


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Journal of Laboratory Physicians
Verified
Journal Article
Open access
PDF file
BTBansidhar Tarai
Bansidhar Tarai
PDPoonam Das
Poonam Das
DKDilip Kumar
Dilip Kumar
Gram-positive pathogens mainly, Staphylococcus aureus, Enterococcus and coagulase-negative Staphylococcus, are developing increasing resistance to glycopeptides that pose a problem in treating infections caused by these pathogens. Vancomycin is the treatment of choice in treating methicillin-resistant S. aureus (MRSA). Community-acquired MRSA is associated with infections in patients without recent history of hospital admission and without the classical risk factors for MRSA carriage (including healthcare personnel). MRSA poses new threats and challenges beyond the hospital with the emergence of community-acquired MRSA. Indiscriminate use of vancomycin leads to the emergence and spread of vancomycin resistance in multidrug resistant strains is of growing concern in the recent years. Minimum Inhibitory concentration (MIC) remains an important determinant in choosing the right antibiotics. Infections caused by MRSA strains with vancomycin MIC > 4 μg/mL leads to the vancomycin treatment failure. The Clinical Laboratory Standards Institute had also lowered the cut-off susceptibility and resistance breakpoints for vancomycin. Despite the availability of newer antimicrobial agents (Linezolid, Daptomycin, Tigecycline) for drug-resistant Gram-positive pathogens, clinicians and patients still need options for treatment of MRSA infection. There is a need to reduce the global burden of infections caused by Gram-positive pathogens and its resistant strains (mainly MRSA). Continuous efforts should be made to prevent the spread and the emergence of glycopeptide resistance by early detection of the resistant strains and using the proper infection control measures in the hospital setting.

25 August 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
MGMahmoud Ghannoum
Mahmoud Ghannoum
Maiken ArendrupMaiken Arendrup
Maiken Arendrup
VCVishnu P. Chaturvedi
Vishnu P. Chaturvedi
Shawn R LockhartShawn R Lockhart
Shawn R Lockhart
TMThomas McCormick
Thomas McCormick
TWThomas J. Walsh
Thomas J. Walsh
Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only available intravenously and are associated with increasingly higher rates of resistance by C. auris. Thus, a need exists for novel treatments that demonstrate potent activity against C. auris. Ibrexafungerp is a first-in-class triterpenoid antifungal agent. Similar to echinocandins, ibrexafungerp inhibits (1→3)-β-D-glucan synthase, a key component of the fungal cell wall, resulting in fungicidal activity against Candida spp. Ibrexafungerp demonstrates broad in vitro activity against various Candida spp. including C. auris and C. auris isolates with fks mutations. Minimum inhibitory concentration (MIC50 and MIC90) values in >400 C. auris isolates were 0.5 μg/mL and 1.0 μg/mL, respectively. Clinical results were reported for two patients with invasive candidiasis or candidemia due to C. auris treated during the CARES (Candidiasis Caused by Candida Auris) trial, an ongoing open-label study. These patients experienced a complete response after treatment with ibrexafungerp. Thus, ibrexafungerp represents a promising new antifungal agent for treating C. auris infections.


1 March 2018 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BTBansidhar Tarai
Bansidhar Tarai
DJDinesh Jain
Dinesh Jain
PDPoonam Das
Poonam Das
SBSandeeep Budhiraja
Sandeeep Budhiraja

22 September 2021 in Journal of Virological Methods
Verified
Journal Article
Closed access
AGAkshita Gupta
Akshita Gupta
ASAnushika Soni
Anushika Soni
SRSheetalnath Rooge
Sheetalnath Rooge
DPDiptanu Paul
Diptanu Paul
RAReshu Agarwal
Reshu Agarwal
EGEkta Gupta
Ekta Gupta

8 August 2022 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
BTBansidhar Tarai
Bansidhar Tarai
PSPoornima Sen
Poornima Sen
RKRimjhim Kanaujia
Rimjhim Kanaujia
JKJasleen Kaur
Jasleen Kaur
MBManisha Biswal
Manisha Biswal
PDPoonam Das
Poonam Das